ProteoCIT

PreclinicalSmall molecule

UUniversity Hospital, Grenoble

ProteoCIT is one of 16 small molecule programs targeting Respiratory Failure. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Respiratory FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Respiratory Failure

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

1 2

Amidate

Plaquenil

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

3 5

Duragesic

CCephalon

Approved

1 6

Inomax

MMallinckrodt

Approved

—7

Ketalar

AAultman Health Foundation

Approved

—8

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Approved

—9

Decadron

AAspen Global Incorporated

Approved

—10

Proair HFA

GGlaxo Dba Glaxosmithkline

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Failure1 trial

Severe Chronic Respiratory Failure and Citrulline

Unknown status·UUniversity Hospital, Grenoble·N/A·NCT03694964·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ProteoCIT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ProteoCIT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ProteoCIT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Grenoble company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Grenoble

ProteoCIT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Failure1 trial

References

Drug Info

Quick Facts

Related News